When the voters of California approved Proposition 14 last November (thanks folks) they gave us $5.5 billion to continue the work we started way back in 2014. It’s a great honor, and a great responsibility. It’s also a great opportunity to look at what we do and how we do it and try to come … Continue reading We’ve got cash, here’s how you can get some
Cell Type
Heads or tails? Stem cells help guide the decision
Two cell embryo There are many unknown elements for what triggers the cells in an embryo to start dividing and multiplying and becoming every single cell in the body. Now researchers at the Gladstone Institutes in San Francisco have uncovered one of those elements, how embryos determine which cells become the head and which the … Continue reading Heads or tails? Stem cells help guide the decision
CIRM funded trial for AMD shows promising results
This upcoming July is healthy vision month, a time to remember the importance of making vision and eye health a priority. It's also a time to think about the approximately 12 million people, 40 and over in the United States, that have a vision impairment. Vision can be something that many of us take for … Continue reading CIRM funded trial for AMD shows promising results
An Open Letter to CIRM for World Sickle Cell Day
Nancy M. Rene Dear CIRM, World Sickle Cell Day is this Saturday June 19th. The goal of this day is to increase knowledge of the disease and understanding of the challenges faced. It is a day that I greet with very mixed feelings. I’m of course extremely grateful to CIRM for the time and money … Continue reading An Open Letter to CIRM for World Sickle Cell Day
Sometimes a cold stare is a good thing
A retina of a patient with macular degeneration. (Photo credit: Paul Parker/SPL) Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness in the elderly in the U.S. It’s estimated that some 11 million Americans could have some form of the disease, a number that is growing every year. So if you … Continue reading Sometimes a cold stare is a good thing
CIRM-catalyzed spinout files for IPO to develop therapies for genetic diseases
Graphite Bio, a CIRM-catalyzed spinout from Stanford University that launched just 14 months ago has now filed the official SEC paperwork for an initial public offering (IPO). The company was formed by CIRM-funded researchers Matt Porteus, M.D., Ph.D. and Maria Grazia Roncarolo, M.D. Six years ago, Dr. Porteus and Dr. Roncarolo, in conjunction with Stanford … Continue reading CIRM-catalyzed spinout files for IPO to develop therapies for genetic diseases
CIRM funded trial may pave way for gene therapy to treat different diseases
Image Description: Jordan Janz (left) and Dr. Stephanie Cherqui (right) According to the National Organization for Rare Disorders (NORD), a disease is consider rare if it affects fewer than 200,000 people. If you combine the over 7,000 known rare diseases, about 30 million people in the U.S. are affected by one of these conditions. A … Continue reading CIRM funded trial may pave way for gene therapy to treat different diseases
Paving the Way
When someone scores a goal in soccer all the attention is lavished on them. Fans chant their name, their teammates pile on top in celebration, their agent starts calling sponsors asking for more money. But there’s often someone else deserving of praise too, that’s the player who provided the assist to make the goal possible … Continue reading Paving the Way
CIRM Builds Out World Class Team With 5 New hires
Kevin Marks, CIRM's new General Counsel. Photo courtesy Modern-Counsel.com Following the passage of Proposition 14 CIRM has hired five new employees to help increase the team’s ability to respond to new challenges and responsibilities. Prop 14, which was approved by voters in November 2020, gives CIRM $5.5 billion in new funding. Those funds mean CIRM … Continue reading CIRM Builds Out World Class Team With 5 New hires
Medeor Therapeutics Completes Enrollment in CIRM-Funded Clinical Trial for Kidney Transplant Patients
A CIRM-funded clinical trial to help kidney transplant patients avoid the need for anti-rejection or immunosuppressive medications has completed enrollment and transplantation of all patients. Medeor Therapeutics’ MDR-101 Phase 3 multi-center clinical trial involved 30 patients; 20 of them were treated with MDR-101, and 10 control subjects were given standard care. CIRM awarded Medeor, based … Continue reading Medeor Therapeutics Completes Enrollment in CIRM-Funded Clinical Trial for Kidney Transplant Patients
The Stem Cellar 